Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Publisher Correction: Molecular factors predicting minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

  • By

  • Florence Magrangeas

  • Mia Cherkaoui

  • Victor Bessonneau-Gaborit

  • Jennifer Derrien

  • Céline Chevalier

  • Catherine Guérin-Charbonnel

  • Benjamin Diamond

  • Mehmet Kemal Samur

  • Cyrille Hulin

  • Denis Caillot

  • Lionel Karlin

  • Bertrand Arnulf

  • Ola Landgren

  • Nikhil C. Munshi

  • Hervé Avet-Loiseau

  • Ludovic Martinet

  • Jill Corre

  • Aurore Perrot

  • Philippe Moreau

  • Cyrille Touzeau

  • Stéphane Minvielle

  • Eric Letouzé

  • November 3, 2026

Share

Objective:

To correct incomplete wording in the abstract of the original article.

Approach:
  • Correction: The abstract’s seventh and eighth sentences were amended.
  • Availability: The corrected text appears in the HTML and PDF versions.
Key Findings:
  • The correction was published online on 19 October 2026.
Interpretation:

The notice reports an abstract wording correction; it does not describe changes to the study findings.

Sources:

Original Source(s)

Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

  • by Florence Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit, Jennifer Derrien, Céline Chevalier, Catherine Guérin-Charbonnel, Benjamin Diamond, Mehmet Kemal Samur, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Ola Landgren, Nikhil C. Munshi, Hervé Avet-Loiseau, Ludovic Martinet, Jill Corre, Aurore Perrot, Philippe Moreau, Cyrille Touzeau, Stéphane Minvielle, Eric Letouzé

  • November 3, 2026

Related Content

Roswell Park is a Center of Excellence for Rectal Cancer Surgery

Roswell Park Comprehensive Cancer Center is a nationally accredited and certified Center of Excellence for colorectal cancer surgery due to the high volume of procedures completed annually for patients with colon and rectal cancer.

  • October 27, 2026

  • 2 min
Can Immunopeptidomics Redefine Cancer Immunotherapy Development?

Immunopeptidomics is helping researchers identify tumor-presented antigens that could inform the development of targeted cell therapies and personalized cancer vaccines

Risk-Based Lung Cancer Screening for People Who Never Smoked